Nitric oxide inhalation modulates endothelin-1 plasma concentration gradients following left ventricular assist device implantation.
Inhaled nitric oxide (iNO) therapy is an effective treatment of pulmonary hypertension following left ventricular assist device (LVAD) implantation. As iNO may also modulate circulating endothelin-1 (ET-1) and big endothelin following LVAD implantation, we investigated the effects of iNO on ET-1 and big endothelin plasma concentration gradients. In order to assist weaning from cardiopulmonary bypass, iNO was administered to 15 consecutive patients with secondary pulmonary hypertension following implantation of a LVAD. Central venous, pulmonary arterial and arterial ET-1 and big endothelin plasma levels were measured preoperatively, on cardiopulmonary bypass prior to iNO administration, 12, 24 and 48 hours postoperatively, and 72 hours after weaning from iNO. The ET-1 gradients between central venous and pulmonary arterial plasma levels decreased significantly with time, and there was a trend for lower arterial-pulmonary arterial plasma concentration gradients. Big endothelin plasma concentration gradients were not altered significantly. The decrease in ET-1 plasma concentration gradients during and after iNO administration may reflect a restoration of the physiologic balance between the different vascular beds. This provides further evidence that intermittent iNO therapy may modulate ET-1 after LVAD implantation.
Wagner
Frank
F
Deutsches Herzzentrum Berlin, Germany.
Buz
Semih
S
Neumeyer
Hans-H
HH
Hetzer
Roland
R
Hocher
Berthold
B
D000280:Administration, Inhalation; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002303:Cardiac Output, Low / Q000150:complications / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D002315:Cardiopulmonary Bypass; D002496:Central Venous Pressure / Q000187:drug effects; D015536:Down-Regulation; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D018497:Ventricular Dysfunction, Right / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology
D000959:Antihypertensive Agents; D019332:Endothelin-1; D009569:Nitric Oxide